Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
about
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsQuality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaIncreases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaHas the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?In silico study supports the efficacy of a reduced dose regimen for stavudine.
P2860
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@en
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@nl
type
label
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@en
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@nl
prefLabel
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@en
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@nl
P2093
P50
P356
P1433
P1476
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
@en
P2093
Amandine Cournil
Christian Laurent
Claudine Ntsama Essomba
Clément Auguste Djouatsa Tonfack
Magloire Biwolé-Sida
Mathilde Coudray
P304
P356
10.3851/IMP1664
P577
2010-01-01T00:00:00Z